Global Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Research Report 2023

Publication ID:

PB502241042

Publication Date:

February 9, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months.
Highlights
The global Rx Irritable Bowel Syndrome (IBS) Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Rx Irritable Bowel Syndrome (IBS) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Rx Irritable Bowel Syndrome (IBS) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Rx Irritable Bowel Syndrome (IBS) Drugs in Women is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Rx Irritable Bowel Syndrome (IBS) Drugs include Ironwood Pharmaceuticals, Bausch Health, Takeda, Sebela Pharmaceuticals and Allergan, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rx Irritable Bowel Syndrome (IBS) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rx Irritable Bowel Syndrome (IBS) Drugs.
The Rx Irritable Bowel Syndrome (IBS) Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Rx Irritable Bowel Syndrome (IBS) Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rx Irritable Bowel Syndrome (IBS) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Ironwood Pharmaceuticals
Bausch Health
Takeda
Sebela Pharmaceuticals
Allergan
Segment by Type
IBS-D Drugs
IBS-C Drugs
Others
Segment by Application
Women
Men
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rx Irritable Bowel Syndrome (IBS) Drugs companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 IBS-D Drugs
1.2.3 IBS-C Drugs
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Women
1.3.3 Men
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Perspective (2018-2029)
2.2 Rx Irritable Bowel Syndrome (IBS) Drugs Growth Trends by Region
2.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Rx Irritable Bowel Syndrome (IBS) Drugs Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Rx Irritable Bowel Syndrome (IBS) Drugs Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Dynamics
2.3.1 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Trends
2.3.2 Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Drivers
2.3.3 Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Challenges
2.3.4 Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rx Irritable Bowel Syndrome (IBS) Drugs Players by Revenue
3.1.1 Global Top Rx Irritable Bowel Syndrome (IBS) Drugs Players by Revenue (2018-2023)
3.1.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Rx Irritable Bowel Syndrome (IBS) Drugs Revenue
3.4 Global Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Concentration Ratio
3.4.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rx Irritable Bowel Syndrome (IBS) Drugs Revenue in 2022
3.5 Rx Irritable Bowel Syndrome (IBS) Drugs Key Players Head office and Area Served
3.6 Key Players Rx Irritable Bowel Syndrome (IBS) Drugs Product Solution and Service
3.7 Date of Enter into Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Rx Irritable Bowel Syndrome (IBS) Drugs Breakdown Data by Type
4.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Forecasted 麻豆原创 Size by Type (2024-2029)
5 Rx Irritable Bowel Syndrome (IBS) Drugs Breakdown Data by Application
5.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size (2018-2029)
6.2 North America Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Country (2018-2023)
6.4 North America Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size (2018-2029)
7.2 Europe Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Country (2018-2023)
7.4 Europe Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size (2018-2029)
9.2 Latin America Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ironwood Pharmaceuticals
11.1.1 Ironwood Pharmaceuticals Company Detail
11.1.2 Ironwood Pharmaceuticals Business Overview
11.1.3 Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.1.4 Ironwood Pharmaceuticals Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2018-2023)
11.1.5 Ironwood Pharmaceuticals Recent Development
11.2 Bausch Health
11.2.1 Bausch Health Company Detail
11.2.2 Bausch Health Business Overview
11.2.3 Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.2.4 Bausch Health Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2018-2023)
11.2.5 Bausch Health Recent Development
11.3 Takeda
11.3.1 Takeda Company Detail
11.3.2 Takeda Business Overview
11.3.3 Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.3.4 Takeda Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2018-2023)
11.3.5 Takeda Recent Development
11.4 Sebela Pharmaceuticals
11.4.1 Sebela Pharmaceuticals Company Detail
11.4.2 Sebela Pharmaceuticals Business Overview
11.4.3 Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.4.4 Sebela Pharmaceuticals Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2018-2023)
11.4.5 Sebela Pharmaceuticals Recent Development
11.5 Allergan
11.5.1 Allergan Company Detail
11.5.2 Allergan Business Overview
11.5.3 Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.5.4 Allergan Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2018-2023)
11.5.5 Allergan Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Ironwood Pharmaceuticals
Bausch Health
Takeda
Sebela Pharmaceuticals
Allergan

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.